INOVIO to Present at Upcoming Investor Conferences in September
INOVIO (NASDAQ:INO) has announced that Dr. Joseph Kim, President and CEO, will present at three upcoming investor conferences in September 2021. The conferences include:
- H.C. Wainwright 23rd Annual Global Investment Conference - Sept 13-15, recorded presentation available on-demand.
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit - Sept 21, at 9:55 AM ET, fireside chat format.
- Cantor Fitzgerald Healthcare Conference - Sept 27, at 10:00 AM ET, fireside chat format.
Details on accessing these presentations can be found on INOVIO's Investor Relations page.
- None.
- None.
PLYMOUTH MEETING, Pa., Sept. 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September:
H.C. Wainwright 23rd Annual Global Investment Conference
Date: September 13-15, 2021
Time: Recorded presentation will be available on-demand
Presentation Format: Fireside Chat
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 21, 2021
Time: 9:55 AM ET
Presentation Format: Fireside Chat
Cantor Fitzgerald Healthcare Conference
Date: Monday, September 27, 2021
Time: 10:00 AM ET
Presentation Format: Fireside Chat
Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events page and may be accessed by visiting INOVIO's website at https://ir.inovio.com/events-and-presentations/default.aspx . All presentation times are subject to change.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, the first of two, Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV-16/18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea.
Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit www.inovio.com.
CONTACTS:
Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com
This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our plans and expectations regarding manufacturing, our plans regarding development of an in-vitro diagnostic, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studies and clinical trials and the availability and timing of data from those studies and trials, and our ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, the structuring, initiation and outcomes of clinical trials, product development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2020, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
View original content:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-investor-conferences-in-september-301367055.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
What dates will INOVIO present at investor conferences in September 2021?
What is the format of INOVIO's presentations at the investor conferences?
Where can I access INOVIO's conference presentations?
Who is presenting for INOVIO at the investor conferences?
What is INOVIO's focus as a biotechnology company?
